Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells.

Autor: Maldini CR; Beam Therapeutics, Cambridge, MA 02142, USA. Electronic address: cmaldini@beamtx.com., Messana AC; Beam Therapeutics, Cambridge, MA 02142, USA., Bendet PB; Beam Therapeutics, Cambridge, MA 02142, USA., Camblin AJ; Beam Therapeutics, Cambridge, MA 02142, USA., Musenge FM; Beam Therapeutics, Cambridge, MA 02142, USA., White ML; Beam Therapeutics, Cambridge, MA 02142, USA., Rocha JJ; Beam Therapeutics, Cambridge, MA 02142, USA., Coholan LJ; Beam Therapeutics, Cambridge, MA 02142, USA., Karaca C; Beam Therapeutics, Cambridge, MA 02142, USA., Li F; Beam Therapeutics, Cambridge, MA 02142, USA., Yan B; Beam Therapeutics, Cambridge, MA 02142, USA., Vrbanac VD; Hummanized Immune System Mouse Program, Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA 02139, USA., Marte E; Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA 02139, USA., Claiborne DT; Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA 02139, USA; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA., Boutwell CL; Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA 02139, USA., Allen TM; Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA 02139, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Oct 02; Vol. 32 (10), pp. 3485-3503. Date of Electronic Publication: 2024 Sep 01.